Steven Cohen Athira Pharma, Inc. Transaction History

Point72 Asset Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.9 - $3.16 $4,090 - $6,803	2,153 Added 0.24%	907,558 $1.83 Million
Q2 2023 Aug 14, 2023	BUY	$2.36 - $3.59 $2.14 Million - $3.25 Million	905,405 New	905,405 $2.67 Million
Q2 2022 Aug 15, 2022	SELL	$2.74 - $13.43 $1.95 Million - $9.58 Million	-713,100 Reduced 92.84%	55,000 $168,000
Q1 2022 May 16, 2022	BUY	$8.96 - $13.51 $6.21 Million - $9.36 Million	693,100 Added 924.13%	768,100 $10.4 Million
Q4 2021 Feb 14, 2022	BUY	$9.17 - $16.39 $687,750 - $1.23 Million	75,000 New	75,000 $977,000
Q3 2021 Nov 15, 2021	SELL	$9.15 - $11.09 $1.82 Million - $2.21 Million	-199,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$10.24 - $20.87 $2.5 Million - $5.1 Million	-244,200 Reduced 55.1%	199,000 $2.04 Million
Q1 2021 May 17, 2021	BUY	$16.9 - $29.77 $7.49 Million - $13.2 Million	443,200 New	443,200 $8.16 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $24.6M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.